What Illimis Therapeutics does

Illimis Therapeutics is a Seoul-headquartered, preclinical biotechnology company founded in 2021 that develops therapeutic candidates for neurodegenerative and autoimmune diseases using its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform — a bispecific fusion protein technology that mounts an amyloid/misfolded-protein target binder on one side and an engineered Gas6 TAM receptor binder on the other. The platform enables TAM receptor-dependent phagocytosis of misfolded proteins without triggering NF-kB-mediated inflammatory responses, positioning it to address the ARIA (Amyloid-Related Imaging Abnormalities) safety limitations of current Alzheimer's antibody therapies. The pipeline comprises five candidates: ILM01 (lead, Aβ-targeting for Alzheimer's, preclinical with IND targeted by end of 2027), ILM02 (tau, for tauopathies including Progressive Supranuclear Palsy), ILM03 (α-synuclein, for Parkinson's and related synucleinopathies), ILM21 (myelin debris, for Multiple Sclerosis), and ILM24 (phosphatidyl serine, for Systemic Lupus Erythematosus).

The company operates a research-driven business model with no commercial revenue. Future monetization is expected through either direct commercialization of approved therapeutics, out-licensing deals, or strategic partnerships with global pharmaceutical companies. Currently, the company generates no product revenue; its funding base of approximately $66.4 million USD comes from venture capital (Series B led by DSC Investment with 18 institutional investors) and Korean government R&D programs including Baby Unicorn, Scale-up TIPS, DCP, and Global Collaborative R&D designations. Scientific credibility is anchored by Nature Medicine publication (2022, IF=87.241), 7 patent families filed (granted in US, Korea, Russia), and co-founders Professor Wonsuk Chung (KAIST) and Professor Chanhyuk Kim (Seoul National University), with SAB members including Dr. Greg Lemke (Salk Institute) and Dr. Morgan Sheng (Broad Institute/Genentech).

The go-to-market motion relies on strategic pharma partnerships and academic collaborations rather than direct sales, with Eli Lilly's Catalyze360-ExploR&D collaboration (Oct 2024) and physical residency at Lilly Gateway Labs in Boston (Sept 2025) representing the most material validation events. The company also maintains JLABS Singapore membership (J&J), won the Seoul-BMS Innovation Square Challenge (2023), and is partnered with David Baker's lab at University of Washington and the Hubrecht Institute on AI-based next-generation Alzheimer's therapeutics. Customer/end-market segments are defined by therapeutic indication rather than commercial buyer: Alzheimer's disease patients (primary), broader neurodegenerative disease patients, and autoimmune disease patients (MS, SLE). With 45 employees (18 PhDs) and operations in Seoul and Boston, the company is scaling organizational capabilities in CMC, protein engineering, and regulatory affairs to support its 2027 IND submission milestone.

Name

Illimis Therapeutics

Legal name

Illimis Therapeutics (일리미스테라퓨틱스 주식회사)

Website

https://illimistx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Illimis Therapeutics is a Seoul-based preclinical biotechnology company developing the GAIA bispecific fusion protein platform to clear misfolded proteins without inflammation, targeting Alzheimer's disease, Parkinson's, Multiple Sclerosis, and SLE via five pipeline candidates with lead ILM01 targeting IND by end of 2027.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

akta.pro secondary industry

Fusion Proteins & Fc-Engineered Biologics (HLAAAAAD)

Keywords

• Neurodegenerative therapeutics
• Bispecific fusion proteins
• Alzheimer's drug development
• Immunotherapy platform
• Preclinical biotechnology

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Drug Development and Commercialization: Pre-revenue biotechnology company developing innovative therapeutics for neurodegenerative and immune diseases. The company is in preclinical development stage with lead candidate ILM01 targeting Alzheimer's disease. Revenue will be generated through eventual drug sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Illimis Therapeutics develops a pipeline of therapeutic candidates for neurodegenerative and autoimmune diseases using its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform—a bispecific chimeric fusion protein technology that clears misfolded proteins via TAM receptor-mediated phagocytosis without triggering inflammatory responses. The company's lead candidate ILM01 targets amyloid-beta for Alzheimer's disease, with additional candidates addressing tauopathies, Parkinson's disease, Multiple Sclerosis, and Systemic Lupus Erythematosus.

Product overview

Illimis Therapeutics is a pioneering biotechnology company developing innovative therapies for challenging central nervous system (CNS) and immune-related diseases. Its core offering is the proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform — a bispecific chimeric fusion protein technology that mounts amyloid target binders to engineered Gas6 TAM receptor binders, enabling clearance of misfolded proteins via TAM receptor-dependent phagocytosis without triggering inflammatory responses. The GAIA platform serves as the foundation for a pipeline of therapeutic candidates: ILM01 (amyloid-beta targeting Alzheimer's disease, lead candidate entering preclinical stage), ILM02 (tau targeting tauopathies), ILM03 (alpha-synuclein targeting Parkinson's disease), ILM21 (myelin debris targeting Multiple Sclerosis), and ILM24 (phosphatidyl serine targeting SLE). The company's AD MOONSHOT program applies GAIA-Aβ to address ARIA, a critical unmet need in current Alzheimer's immunotherapy.

Differentiator

Problem solved

Functional benefit

Brands

• GAIA Platform: Gas6-mediated Anti-Inflammatory Adaptor platform - a bispecific fusion protein technology for developing treatments targeting misfolded proteins without inflammatory side effects.
• GAIA-Aβ

Products and services

• GAIA Platform GAIA (Gas6-mediated Anti-Inflammatory Adaptor) is a bispecific chimeric fusion protein platform that mounts an amyloid target binder on one side and an engineered Gas6 TAM receptor binder on the other, enabling clearance of misfolded proteins via TAM receptor-dependent phagocytosis without inducing NF-kB-mediated inflammatory responses. It is the foundational technology licensed and applied across Illimis's therapeutic pipeline for neurodegenerative and immune diseases.
• ILM01 ILM01 is Illimis Therapeutics' lead pipeline candidate targeting amyloid-beta (Aβ) for the treatment of Alzheimer's disease, leveraging the GAIA platform to address ARIA (Amyloid-Related Imaging Abnormalities), a common side effect of existing antibody immunotherapies. It is positioned for IND submission by end of 2027.
• ILM02 ILM02 is a pipeline candidate targeting tau for the treatment of tauopathies, including Progressive Supranuclear Palsy, developed using the GAIA platform.
• ILM03 ILM03 is a pipeline candidate targeting alpha-synuclein (α-Syn) for potential application in Parkinson's disease and related synucleinopathies, based on the GAIA platform.
• ILM21 ILM21 is a pipeline candidate targeting myelin debris for the treatment of Multiple Sclerosis, leveraging the GAIA platform's TAM receptor-mediated phagocytosis approach.
• ILM24 ILM24 is a pipeline candidate targeting phosphatidyl serine (PS) for the treatment of Systemic Lupus Erythematosus (SLE), developed using the GAIA platform.
• GAIA-Aβ Moonshot Program GAIA-Aβ is Illimis Therapeutics' moonshot program applying the GAIA platform to amyloid-beta clearance for Alzheimer's disease, with the explicit goal of addressing ARIA (Amyloid Related Imaging Abnormalities) as a critical unmet need of existing Alzheimer's treatments, showing substantially reduced synapse elimination and microhemorrhage compared to Aducanumab in preclinical studies.

Quantifiable outcome

• Better behavioral outcomes with substantially reduced synapse elimination and microhemorrhage compared to Aducanumab in preclinical studies
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• Lilly Gateway LabscoreStrategic or Co-development Partner · 1 September 2025Company established research base at Lilly Gateway Labs in Boston starting September 2025, gaining access to state-of-the-art lab space, operational support, and collaboration opportunities with Lilly researchers in neurodegenerative disease fields.
• David Baker (University of Washington)majorStrategic or Co-development Partner · 1 January 2025Selected for Ministry's Global Collaborative R&D program with David Baker (2024 Nobel Prize in Chemistry laureate) as partner. Baker's institute handles BBB permeability shuttle development and Alzheimer's pathology targeting protein design. Collaboration involves AI-based next-gen Alzheimer's treatment development over 3 years with 2.8 billion KRW funding.
• Hubrecht Institute (Netherlands)minorStrategic or Co-development Partner · 1 January 2025Research partner in Global Collaborative R&D program, with Dr. Danny Sahtoe serving as expert in protein design for degenerative brain disease treatment, responsible for structural and functional verification of designed proteins.
• Korea Dementia Research CenterminorStrategic or Co-development Partner · 1 January 2025Selected for '2025 Global Joint Research to Defeat Dementia' program led by Ministry of Health and Welfare and Korean Dementia Research Center, securing KRW 2.2 million ($1.6 million) in funding over three years.
• Eli Lilly and Company (Catalyze360-ExploR&D)coreStrategic or Co-development Partner · 1 October 2024Strategic research collaboration with Lilly's external innovation program to advance the GAIA platform construct for applications in neurodegenerative diseases. The collaboration involves advancement of platform technology for therapeutic development using Lilly's research and development capabilities.
• Johnson & Johnson (JLABS Singapore)majorStrategic or Co-development Partner · 1 January 2024Joined Johnson & Johnson's global incubator network as a member company of JLABS Singapore, gaining access to J&J's ecosystem and resources for biotech development.
• Bristol-Myers Squibb KoreamajorStrategic or Co-development Partner · 1 November 2023Won the Seoul-BMS Innovation Square Challenge organized by BMS Korea, receiving research support for immune disease therapeutic development.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Alector: Alector is a clinical-stage neuro-immunology biotech developing therapeutics that engage the brain's immune system to treat neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. Comparable to Illimis in targeting neuroinflammation/microglial pathways for CNS disease, though Alector focuses on TREM2/progranulin biology rather than TAM receptors.
• Annexon: Annexon is a clinical-stage biotech developing therapeutics that inhibit classical complement pathway for neurodegenerative and autoimmune diseases. Directly comparable as a neuro-immunology platform targeting CNS diseases via immune modulation, with parallel pre-clinical/early clinical stage assets.
• Denali Therapeutics: Denali Therapeutics is a clinical-stage biotech developing therapeutics for neurodegenerative diseases using its proprietary BBB Shuttle technology and protein engineering platform. Comparable as a platform-based neurodegeneration company with multiple CNS pipeline programs targeting protein aggregation and lysosomal function.
• Prothena: Prothena is a clinical-stage biotech developing protein immunotherapies for neurodegenerative diseases including Alzheimer's (PRX012) and Parkinson's. Closely comparable in using engineered biologics to clear misfolded proteins (Aβ, α-Syn, tau) in CNS disease, with overlapping target portfolio to Illimis.
• Cognition Therapeutics: Cognition Therapeutics is a clinical-stage biotech developing small molecules and biologics for Alzheimer's disease and other neurodegenerative conditions. Comparable as an early-stage company targeting CNS proteinopathies with mechanism-based therapeutic approach.
• Athira Pharma: Athira Pharma is a clinical-stage biotech developing small molecules targeting the HGF/MET neurotrophic system for neurodegenerative diseases including Alzheimer's. Comparable stage and indication focus though different mechanism.
• Cassava Sciences: Cassava Sciences is a clinical-stage biotech developing therapeutics for Alzheimer's disease, including simufilam. Comparable as a small-cap, controversy-prone CNS biotech focused on Alzheimer's pathology through novel mechanism.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is an established commercial-stage RNAi therapeutics company. Relevant as a broader incumbent platform-based biologics company that validates the therapeutic biologics model in CNS/rare diseases and serves as a strategic comp for what Illimis could become at scale.
• Eli Lilly: Eli Lilly is a global pharmaceutical company with a major Alzheimer's franchise (Kisunla/donanemab) and CNS pipeline. Directly relevant as both a strategic partner (Catalyze360, Gateway Labs) and the dominant incumbent competitor in the Alzheimer's therapeutic space.
• Eisai: Eisai is a global pharmaceutical company with Leqembi (lecanemab) for Alzheimer's disease. Relevant as the established anti-Aβ antibody market leader that Illimis aims to compete with via differentiated ARIA-avoiding mechanism.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Illimistx
• YouTubeyoutube.com/channel/UC3tRHPdwDnYWLu6AFsxyyUw
• LinkedInlinkedin.com/company/illimis-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Illimis Therapeutics